Having established success in cancer, biopharma is now looking to leverage CAR T therapies against a new target, autoimmune ...

Bristol-Myers Squibb acquires 2seventy bio for $286M, marking the end of a once-promising biotech. Check out if this is a ...

René Myers, have always been close. But five years ago, they discovered something that brought them even closer: a shared diagnosis of the connective tissue disorder Ehlers-Danlos Syndrome (EDS).

Investors are encouraged to read the Company's Annual Report on Form 10-K when it is filed with the Securities and Exchange ...

Three months after Bristol Myers Squibb revealed the success of two phase 3 trials of its oral targeted therapy Sotyktu in ...

Culton and Myers stressed the importance of raising awareness about these rare diseases and of getting more physicians and ...

Quoin Pharmaceuticals (QNRX) announced recent corporate accomplishments and provided an update on its fourth quarter and full-year 2024 ...

Why have BMS investors been anything but positive about acquiring 2seventy? The answer stems from uncertainty over how ...

Treatment Market is expected to grow steadily, driven by the rising prevalence of hormonal disorders, infertility, and ...

Bristol Myers Squibb gets European Commission approval to expand use of CAR T cell therapy, Breyanzi for relapsed or refractory follicular lymphoma: Princeton, New Jersey Monday, ...

Princeton: Bristol Myers Squibb has announced that the European Commission (EC) has granted approval to Breyanzi ...